Goserelin

Adults: Goserelin 3.6 mg is given under the skin (subcutaneously) every 28 days, into the front wall of the abdomen below the navel line. A doctor should supervise it, and an aseptic technique must be used. A delay of a few days is allowed, but every effort should be made to keep to the 28-day schedule. Stage B2-C Prostatic Carcinoma When Goserelin is given together with radiotherapy and flutamide for patients with Stage T2b-T4 (Stage B2-C) prostatic carcinoma, treatment should start 8 weeks before radiotherapy begins and carry on during the radiation therapy. One option is a Goserelin 3.6 mg depot 8 weeks before radiotherapy, followed 28 days later by the Goserelin 10.8 mg depot. The other option is four injections of the 3.6 mg depot at 28-day intervals, with two depots before radiotherapy and two during it. Prostatic Carcinoma For advanced prostate cancer, Goserelin is meant for long-term use unless it is clinically inappropriate. Endometriosis For endometriosis, the recommended duration of treatment is 6 months. There are no clinical data on treating benign gynecological conditions with Goserelin for longer than 6 months. Retreatment cannot be recommended for endometriosis, because no safety data for retreatment are available. If symptoms come back after a course of therapy and further Goserelin treatment is being considered, bone mineral density should be monitored. Clinical studies suggest that adding Hormone Replacement Therapy (estrogens and/or progestins) to Goserelin reduces the bone mineral loss that happens with Goserelin alone. It does this without reducing how well Goserelin relieves the symptoms of endometriosis. Hormone Replacement Therapy may also reduce vasomotor symptoms and vaginal dryness linked to hypoestrogenism. The best drugs, dose and duration of this treatment have not been established. Endometrial Thinning When Goserelin is used to thin the endometrium before endometrial ablation, the recommended dose is one or two depots, given four weeks apart. If one depot is given, surgery should be done at four weeks. If two depots are given, surgery should be done within two to four weeks after the second depot. Breast Cancer For advanced breast cancer, Goserelin is meant for long-term use unless it is clinically inappropriate. Renal or Hepatic Impairment No dose adjustment is needed for patients with renal or hepatic impairment. Goserelin 10.8 mg is given under the skin (subcutaneously) every 12 weeks, into the front wall of the abdomen below the navel line. A doctor should supervise it, and an aseptic technique must be used. A delay of a few days is allowed, but every effort should be made to keep to the 12-week schedule. Stage B2-C Prostatic Carcinoma When Goserelin is given together with radiotherapy and flutamide for patients with Stage T2b-T4 (Stage B2-C) prostatic carcinoma, treatment should start 8 weeks before radiotherapy begins and carry on during the radiation therapy. The regimen is one Goserelin 3.6 mg depot, followed 28 days later by one Goserelin 10.8 mg depot. Prostatic Carcinoma For advanced prostate cancer, Goserelin is meant for long-term use unless it is clinically inappropriate. Renal or Hepatic Impairment No dose adjustment is needed for patients with renal or hepatic impairment. Women Goserelin 10.8 mg implant is not indicated in women, because the data are not enough to support reliable suppression of serum estradiol. Female patients who need goserelin should be treated according to the prescribing information for the Goserelin 3.6 mg implant.